Nautilus Biotechnology Appoints Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development
August 09 2021 - 8:00AM
Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a
company pioneering a single-molecule protein analysis platform for
quantifying the proteome, today announced the appointment of Karl
Voss, Ph.D., as Vice President of Life Sciences Research and
Development. He and his team will work out of Nautilus’ research
headquarters in San Carlos, California.
Dr. Voss brings more than 20 years of experience directing
single-molecule biophysics and biochemistry, cell biology, and
materials science research at leading biotechnology and life
sciences companies. He was previously Vice President of Consumables
Research and Development at Pacific Biosciences, where he led
scientific efforts to productize the company’s long-read,
single-molecule DNA sequencing instruments. Across 13 years, his
roles in the development of the company’s Single Molecule,
Real-Time (SMRT) Sequencing platform included driving the chemistry
underlying SMRT, as well as contributing to instrument and software
integration programs.
“With his deep expertise across research and development in
single-molecule biochemistry, life sciences platforms, and systems
integration, Karl has been instrumental in bringing a foundational
long-read, single-molecule sequencing platform from prototype to
product,” said Parag Mallick, Ph.D., co-founder and Chief Scientist
of Nautilus. “We are excited to welcome him to our team as we seek
to transform our understanding of human biology beyond the genome
and drive the type of fundamental advancements in biomedical
research that we believe our protein analysis platform can make
possible.”
Prior to his work with Pacific Biosciences, Dr. Voss made
substantial contributions at Cell Biosciences and Applied
Biosystems. Dr. Voss received his B.S. in Biochemistry and Ph.D. in
Analytical Chemistry from the University of Alberta.
“Nautilus is taking a truly revolutionary approach to unlocking
the potential of proteomics – a relatively untapped but enormously
valuable source of information about human biology,” said Dr. Voss.
“I’m thrilled to join Nautilus’ stellar leadership team to further
develop the first proteomics platform that will power a new era of
precision therapies, tools, and applications.”
The appointment of Dr. Voss comes shortly after the debut of
Nautilus as a publicly traded company and the appointments of Emma
Lundberg to its Scientific Advisory Board and Matt Murphy as
General Counsel. Nautilus completed a business combination with
Arya Sciences Acquisition Corp III and received gross proceeds from
the transaction totaling approximately $345 million to develop a
protein analysis platform with the potential to quantify more than
95% of the proteome. Through innovations in computer science,
engineering, and biochemistry, the Nautilus Proteomic Analysis
Platform is designed to leverage a nanofabricated, large-scale,
single-molecule protein array, multi-cycle imaging, and machine
learning analysis to measure the proteome with extreme sensitivity
and scale.
About Nautilus Biotechnology, Inc.Based in
Seattle, Washington, Nautilus is a development stage life sciences
company creating a platform technology for quantifying and
unlocking the complexity of the proteome. Nautilus’ mission is to
transform the field of proteomics by democratizing access to the
proteome and enabling fundamental advancements across human health
and medicine. To learn more about Nautilus, visit
www.nautilus.bio
Special Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of federal securities laws. You can
identify forward-looking statements by words such as “may,” “will,”
“could,” “can,” “would,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “project,”
“potential,” “poised,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, but not all
forward-looking statements will contain these words.
Forward-looking statements in this press release include, but are
not limited to, statements regarding the potential functionality
and performance of Nautilus’ product platform, its potential impact
on pharmaceutical development and drug discovery, and market
opportunities available to Nautilus generally. These statements are
based on numerous assumptions concerning the development of
Nautilus’ products and target markets and involve substantial
risks, uncertainties and other factors that may cause actual
results, levels of activity, performance or achievement to be
materially different from the information expressed or implied by
these forward-looking statements. We cannot assure you that the
forward-looking statements in this press release or the assumptions
upon which they are based will prove to be accurate. Risks and
uncertainties that could materially affect the accuracy of
Nautilus’ assumptions and its ability to achieve the
forward-looking statements set forth in this press release include
(without limitation) the following: Nautilus’ product platform is
not yet commercially available and remains subject to significant
scientific and technical development, which is inherently
challenging and difficult to predict, particularly with respect to
highly novel and complex products such as those being developed by
Nautilus. Even if our development efforts are successful, our
product platform will require substantial validation of its
functionality and utility in life science research. In the course
of Nautilus’ scientific and technical development and associated
product validation and commercialization, we may experience
material delays as a result of unanticipated events. We cannot
provide any guarantee or assurance with respect to the outcome of
our development and commercialization initiatives or with respect
to their associated timelines. For a more detailed description of
additional risks and uncertainties facing Nautilus and its
development efforts, investors should refer to the Registration
Statement on Form S-1 and related documents filed with the SEC. The
forward-looking statements in this press release are as of the date
of this press release. Except as otherwise required by applicable
law, Nautilus disclaims any duty to update any forward-looking
statements. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date of this press release.
Disclosure InformationNautilus uses filings
with the Securities and Exchange Commission, its website
(www.nautilus.bio), press releases, public conference calls, public
webcasts, and its social media accounts as means of disclosing
material non-public information and for complying with Regulation
FD.
Media ContactThermal for Nautilus
BiotechnologyKaustuva Daspress@nautilus.bio
Investor
Contactinvestorrelations@nautilus.bio
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nautilus Biotechnology (NASDAQ:NAUT)
Historical Stock Chart
From Apr 2023 to Apr 2024